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ABSTRACT 
Omeprazole  is  a  proton  pump  inhibitor  used  in  the  treatment  of  dyspepsia,  peptic  ulcer  disease  (PUD),  Gastroesophageal  reflux  disease  (GERD), 
laryngopharyngeal reflux disease (LPR) and Zollinger-Ellison syndrome. The present study deals with the formulation of omeprazole fast dissolving tablets 
utilising cross linked alginic acid and calcium silicate as super disintegrates and a total of 8 formulation batches were prepared. All the pre compression and 
post compression parameters are studied and the results comply with in the limits. In vitro dissolution studies explained that the optimised F7 formulation with 
super disintegrants Cross linked alginic acid at low ratio and Calcium silicate at high ratio showed a cumulative release of 99.6 % of drug at the end of 12 
minutes and also exhibited first order kinetics with Higuchi mechanism of drug release.  
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INTRODUCTION 
The Centre for Drug Evaluation and Research (CDER), US 
FDA
1  defined  fast  dissolving  tablets  (FDT)  as  “A  solid 
dosage  form  containing  medicinal  substances,  which 
disintegrate  or  dissolve  rapidly,  usually  within  a  matter  of 
seconds, when placed upon the tongue”.
2 FDTs disintegrate 
and / or dissolve instantaneously in the saliva without the use 
of water. However some patients, particularly paediatrics and 
geriatric patients have trouble in swallowing or chewing solid 
dosage  forms  (conventional  dosage  forms).  To  avert  the 
impediments accompanying with dosage forms like the dry 
syrups and effervescent tablets which require water for their 
action  whereas  the  chewable  tablets  have  the  problem  of 
bitter tasting or unpleasant taste of the drug and injections are 
not preferred due to their intrusiveness. So, the development 
of an appropriate dosage form is most desirable. The concept 
of mouth dissolving drug delivery system emerged from the 
desire to  provide  patient with more conventional  means  of 
taking  their  medication.  The  elementary  methodology  in 
development  of  FDT  is  the  use  of  super  disintegrants  like 
croscarmellose, sodium starch glycolate, cross linked alginic 
acid etc, provide instantaneous disintegration of tablet after 
putting  on  tongue,  there  by  release  the  drug  in  saliva
3,4. 
Omeprazole is a proton pump inhibitor used in the treatment 
of dyspepsia, peptic ulcer disease (PUD), Gastroesophageal 
reflux  disease  (GERD),  laryngopharyngeal  reflux  disease 
(LPR) and Zollinger-Ellison syndrome. It is a selective and 
irreversible  proton  pump  inhibitor  which  suppresses  the 
gastric  acid  secretion  by  specific  inhibition  of  hydrogen-
potassium adenosine triphosphatase (H
+-K
+-ATPase) enzyme 
system found at the secretary surface of the parietal cells. The 
systemic bioavailability is 60 % for repeated doses and the 
absorption is completed within 3-6 h
5,6. The purpose of the 
contemporary  study  is  to  formulate  Omeprazole  fast 
dissolving  tablets  using  super  disintegrants  cross  linked 
alginic  acid  and  calcium  silicate  and  study  there  in  vitro 
performance. 
 
 
 
MATERIALS AND METHODS 
Omeprazole is a gift sample obtained from In ventis Pharma 
Pvt  Ltd, Hyderabad,  India Super disintegrates Cross linked 
alginic acid and calcium silicate were acquired from Rhom 
Pharma.  Micro  crystalline  Cellulose,  sodium  saccharin, 
magnesium  stearate  were  obtained  from  Signet  chemicals. 
Aerosil  was  obtained  from  Aurobindo  Pharma  limited.  All 
the reagents used are of analytical grade.  
 
Construction  of  Standard  Calibration  Curve  for 
Omeprazole 
An  accurately  weighed  100  mg  of  omeprazole  drug  was 
dissolved in 100 ml of 0.05 N HCl
7 and used as primary stock 
solution. From the primary stock, concentrations of 2, 4, 6, 8, 
10 µg / ml were prepared and the absorbance was measured 
at 302 nm using UV-Visible spectrophotometer. A plot was 
drawn taking concentration on x-axis and absorbance on y-
axis and regression was determined as in Figure1. 
 
Physical Evaluation of Powder blend 
The powder blend was studied for angle of repose, bulk and 
tapped densities, compressibility index and Hausner’s ratio
8,9. 
 
Determination of Angle of Repose 
The  flow  property  was  determined  by  the  angle  of  repose 
which is the maximum angle that can be attained between the 
free surfaces of a powder heap with its horizontal plane. The 
formula for calculating angle of repose was: 
 
Θ = tan 
-1(h/r) 
Where, h = height of the pile; r = radius of the pile 
 
Values of θ less than 40° indicate reasonable flow property to 
the powder and value greater than 50° indicates difficulty in 
flow. 
 
Determination  of  Bulk  and  Tapped  Densities, 
Compressibility Index and Hausner’s ratio 
A fixed amount of powder (W) was placed in a measuring 
cylinder and is allowed to fall under its own weight onto a Soumya Missula et al. Int. Res. J. Pharm. 2013, 4 (8) 
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hard surface from a 2.5 cm height at 2 sec time interval. The 
tappings were continued until there were no void spaces and 
the  final  volume  was  noted.  The  bulk  density  and  tapped 
density were calculated using the following formulas:   
 
Bulk density = W / V0 
Tapped density = W / Vf 
Where, W = weight of the powder; V0 = initial volume; Vf = final volume. 
 
Carr’s Compressibility Index 
It  is  measured  from  bulk  and  tapped  densities.  Calculated 
using the formula, 
 
Compressibility index, (CI) = 100 (V0 - Vf) / V0 
 
Hausner’s ratio 
It measured as the ratio of tapped density to the bulk density. 
 
Hausner’s ratio = tapped density / bulk density 
 
Method of Tablet Preparation 
All  the  ingredients  were  accurately  weighed  and  sieved 
through mesh # 36. Except aerosil and talc all the others were 
mixed geometrically. The blend was lubricated later with talc 
and aerosil. Tablets of 200 mg were compressed using 9 mm 
flat face circular punches which were fixed to the 16 station 
single  rotary  tablet  compression  machine  (Cadmach, 
Ahmedabad, India). The prepared tablets were evaluated for 
several post compression parameters like hardness, thickness, 
weight variation, friability, drug content, disintegration time 
and in vitro dissolution studies. Table 1 illustrates the list of 
formulation batches. 
 
Evaluation of Post Compression Parameters 
Thickness
10-12 
The thickness of tablets was estimated using vernier callipers 
expressed in mm. 
 
Hardness 
The formulated tablets were evaluated for hardness using a 
Monsanto hardness tester. The force is applied diametrically 
and  is  expressed  as  kg/cm
2.  Three  tablets  for  each 
formulation were evaluated. 
 
Friability 
The tablets were subjected to combined effects of abrasion 
and shock by placing them in a roche friabilator that revolves 
at 25 rpm for about 4 minutes. Pre-weighed tablets (Wi) were 
subjected to 100 revolutions and later de dusted with a muslin 
cloth and the tablets weight (Wf) was noted. The friability (F) 
can be calculated using 
 
F =             Wi  -  Wf   ×   100 
Wf 
 
Weight Variation 
Twenty  tablets  from  each  formulation  were  taken  and  the 
average  weight  was  noted.  The  individual  weight  was 
compared with the average weight. 
 
Wetting Time 
A petri dish of internal diameter 6.5 cm was taken containing 
10 ml of water with a soluble dye like eosin in which a tissue 
paper folded twice and placed. On the top of it a tablet was 
positioned  and  the  time  for  complete  wetting  was  noted. 
Three trials were performed for each batch. 
 
In vitro Disintegration Test  
The  in  vitro  disintegration  was  implemented  in  USP 
disintegration apparatus. The set-up was done by employing 
six  tablets  in  each  tube  and  the  time  necessary  for  the 
complete disintegration with no palpable mass was noted in 
seconds.  
 
In vitro Dissolution Study  
In  vitro  dissolution  was  done  in  USP  dissolution  type  II 
(paddle) apparatus with 900 ml of phosphate buffer pH 6.8 as 
the medium at 100 rpm and the temperature was maintained 
at 37 ± 0.5°C. 5 ml aliquots were withdrawn at specified time 
intervals of 2, 4, 6, 8, 10 minutes and replaced with equal 
amount  of  buffer  to  sustain  sink  conditions.  The  samples 
were withdrawn and examined spectrophotometrically at 302 
nm using UV-Visible spectrophotometer. 
 
Table 1: List of Ingredients in Formulation Batches (F1-F8) 
 
S. No  Ingredients  F1 (mg)  F2 (mg)  F3 (mg)  F4 (mg)  F5 (mg)  F6 (mg)  F7 (mg)  F8 (mg) 
1  Omeprazole  20  20  20  20  20  20  20  20 
2  Cross linked alginic acid  10  20  -  -  10  20  10  20 
3  Calcium silicate  -  -  40  80  40  80  80  40 
5  Sodium saccharin  2  2  2  2  2  2  2  2 
6  Magnesium stearate  3  3  3  3  3  3  3  3 
7  Aerosil  4  4  4  4  4  4  4  4 
8  Microcrystalline cellulose  161  151  131  91  121  71  81  111 
Total weight (mg)  200  200  200  200  200  200  200  200 
 
Table 2: Results of Pre-Compression Parameters 
 
Formulation 
batch 
Angle of repose (°) 
Mean ± S.D 
Bulk density (gm/cc) 
Mean ± S.D 
Tapped density (gm/cc) 
Mean ± S.D 
Compressibility index (%) 
Mean ± S.D 
Hausner’s ratio 
Mean ± S.D 
F1  28.5 ± 0.85  0.55 ± 0.06  0.65 ± 0.06  15.5 ± 0.52  1.02 ± 0.55 
F2  26.5 ± 0.50  0.45 ± 0.06  0.67 ± 0.05  17.5 ± 0.42  1.05 ± 0.25 
F3  29.7 ± 0.35  0.51 ± 0.03  0.71 ± 0.08  19.8 ± 0.1  1.1 ± 0.15 
F4  28.9 ± 0.85  0.52 ± 0.04  0.65 ± 0.04  16.4 ± 0.55  1.03 ± 0.5 
F5  26.6 ± 0.55  0.49 ± 0.05  0.70 ± 0.06  15.6 ± 0.06  1.15 ± 0.15 
F6  30.5 ± 0.15  0.52 ± 0.02  0.66 ± 0.05  16.9 ± 0.60  1.23 ± 0.12 
F7  31.5 ± 0.65  0.56 ± 0.08  0.63 ± 0.07  15.8 ± 0.25  1.2 ± 0.06 
F8  29.9 ± 0.45  0.55 ± 0.05  0.62 ± 0.06  18.8 ± 0.15  1.22 ± 0.15 
*All values are calculated as Mean ± S.D 
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Table 3: Results of Post-Compression Parameters 
 
Formulation 
batch 
Thickness (mm) 
Mean ± S.D 
Hardness (kg/cm
2) 
Mean ± S.D 
Friability (%) 
Mean ± S.D 
Weight variation 
(mg) Mean ± S.D 
Wetting time (sec) 
Mean ± S.D 
In vitro disintegration 
(sec) Mean ± S.D 
F1  3.24 ± 0.5  3.8 ± 0.65  0.54 ± 0.5  202 ± 0.5  35 ± 0.52  20 ± 0.25 
F2  3.0 ± 0.15  3.74 ± 0.55  0.75 ± 0.15  205 ± 0.6  39 ± 0.25  30 ± 0.33 
F3  3.2 ± 0.26  3.95 ± 0.5  0.64 ± 0.5  195 ± 0.5  36 ± 0.52  22 ± 0.65 
F4  2.9 ± 0.52  3.7 ± 0.15  0.44 ± 0.25  198 ± 0.2  35 ± 0.36  24 ± 0.55 
F5  2.96 ± 0.33  3.9 ± 0.55  0.77 ± 0.6  196 ± 0.6  36 ± 0.92  22 ± 0.45 
F6  3.1 ± 0.65  4.2 ± 0.05  0.65 ± 0.55  204 ± 0.8  42 ± 0.6  28 ± 0.66 
F7  3.3 ± 0.25  4.0 ± 0.35  0.62 ± 0.4  200 ± 0.5  32 ± 0.8  22 ± 0.33 
F8  3.0 ± 0.55  3.95 ± 0.15  0.59 ± 0.15  1992 ± 0.7  37 ± 0.45  27 ± 0.75 
*All values are calculated as Mean ± S.D 
 
Table 4: Kinetic Values Obtained from in vitro-Release Data for Formulations F1-F8 
 
Formulation  Zero order  First order  Higuchi  Korsmeyer Peppas 
code  R value  R value  R value  R value  ‘n’ value (release exponent) 
F1  0.9715  0.9856  0.9598  0.9558  0.4758 
F2  0.9254  0.9563  0.9755  0.9705  0.4561 
F3  0.9156  0.9936  0.9896  0.9567  0.4785 
F4  0.8993  0.9748  0.9963  0.9562  0.4963 
F5  0.9602  0.9686  0.9875  0.8965  0.5444 
F6  0.9795  0.9856  0.9845  0.9561  0.6654 
F7  0.9525  0.9758  0.9777  0.9687  0.5893 
F8  0.9103  0.9315  0.9658  0.9581  0.5677 
 
 
 
Figure 1: Standard Calibration Curve of Omeprazole 
 
 
 
Figure 2: Wetting Time Evaluation of Omeprazole FDTs 
 
 
 
Figure 3: Comparison of in vitro-Disintegration Time and Wetting Time for Formulations F1-F8 
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Figure 4: Cumulative % of Drug Released for Formulations F1-F8 
 
RESULTS AND DISCUSSION 
The fast dissolving omeprazole tablets were designed using 
two super disintegrants Cross linked alginic acid and calcium 
silicate.  A  total  of  8  formulations  were  prepared  and  the 
various quality control tests were adopted in tables 2 and 3. 
There  was  no  significant  weight  variation  observed  within 
average weight and individual weight. The % friability of the 
tablets  was  well  within  the  tolerable  range.  The  tablet 
thickness ranged from 2.9 ± 0.52 to 3.3 ± 0.25. The hardness 
of  tablets  ranged  from  3.7  ±  0.15  to  4.2  ±  0.05.  The  % 
friability ranged from 0.44 ± 0.25 to 0.77 ± 0.6. Wetting time 
corresponds to the time taken for the tablet for the tablet to 
disintegrate when kept motionless on the tongue. The wetting 
time  ranged  from  32  ±  0.25  to  42  ±  0.6.  The  in  vitro 
disintegration time for the formulated tablets ranged from 20 
± 0.25 to 30 ± 0.33. 
 
In vitro Dissolution Studies 
All the 8 formulations were subjected to in-vitro dissolution 
studies by using phosphate buffer as dissolution medium. In-
Vitro  release  studies  of  all  formulations  were  plotted  and 
shown in the Figure 4. Formulations F1, F2 contained low 
and high concentrations of cross linked alginic acid showed 
cumulative drug release of 45.5 % and 65.9 % respectively at 
the end of 15 minutes. Formulation F3 and F4 contained low 
and  high  concentrations  of  calcium  silicate  showed 
cumulative drug release of 59.5 % and 78.5 % respectively at 
the  end  of  15  minutes.  Formulations  F5,  F6,  F7  and  F8 
showed 85.9 %, 89.5 %, 99.6 %, 96.8 % respectively at the 
end of 12 minutes. Out of all eight, F7 showed 99.6 % release 
within 12 minutes. The cumulative % of drug release for all 
formulations  was  shown  in  Figure  4.  The  drug  release 
followed first order kinetics for all formulation batches. (F1-
F8) on the basis of regression value (R value is greater for 
first order). To ascertain the mechanism of drug release the 
data  was  subjected  to  Higuchi  and  korsmeyer  Peppas 
equations  and  the  kinetic  date  was  depicted  in  Table  4. 
Formulations  F1-  F8  showed  Higuchi  mechanism  of  drug 
release.  The  optimised  F7  formulation  with  super 
disintegrants  Cross  linked  alginic  acid  at  low  ratio  and 
Calcium  silicate  at  high  ratio  exhibited  first  order  kinetics 
with Higuchi mechanism of drug release. 
 
 
 
CONCLUSION 
The use of super disintegrants cross linked alginic acid and 
calcium silicate showed faster disintegration and dissolution 
profile. Ideally F7 formulation was considered as optimized 
which showed 99.6 % drug release at the end of 12 minutes. 
All the formulations followed first order kinetics with higuchi 
mechanism of drug release (F1-F8). 
 
ACKNOWLEDGEMENT 
The authors are thankful to NRI college of Pharmacy for providing adequate 
lab facilities in the execution of the work. 
 
REFERENCES 
1.  Seager H. Drug delivery products and the Zydis fast dissolving dosage 
forms.  J.  Pharm.  Pharmacol  1998;  50:  350-382.  http://dx.doi.org/ 
10.1111/j.2042-7158.1998.tb06876.x 
2.  Chang RK, Guo X, Burnside BA and Cough RA. Fast dissolving tablets. 
Pharm. Tech 2000; 24: 52-58.  
3.  Shastry  CS, Srinath MS. Pharmaceutical approaches  of taste  masking 
oral dosage forms, Ind. Drug 2004; 41(5): 253-257.  
4.  Bhushan SY, Sambhaji SP, Anant RP, Mahadik KR. New drug delivery 
system for Elderly, Indian Drugs 2003; 37(7): 312-318. 
5.  www.medicinenet.com/omeprazole/article.html,  Accessed  date: 
08/10/2011    
6.  Drug  Bank,  Canada  (www.drugbank.ca),  Drug  Bank:  Omeprazole 
(DB00338).  Available  from:  www.drugbank.ca/drugs/DB00338, 
Accessed date: 05/10/2011 
7.  Macek  J, Ptacek P,  Klima  J.  Determination  of  omeprazole  in  human 
plasma  by  high-performance  liquid  chromatography.  J.  of 
Chromatography  B  1997;  689:  239-243.  http://dx.doi.org/10.1016/ 
S0378-4347(96)00283-6 
8.  Lakshmi PK, Jyothi G. Comparative evaluation of natural and synthetic 
super  disintegrants  with  newer  super  disintegrant  Kyron  T-314,  Acta 
Pharmaceutica Sciencia 2011; 53: 35–44.  
9.  Chaulang  G,  Patil  K,  Ghodke  D,  Khan  S,  Yeole  P.  Preparation  and 
Characterization  of  Solid  Dispersion  Tablet  of  Furosemide  with 
Formulation  Design  and  Evaluation  of  Mouth  Dissolving  Tablets 
Omeprazole  Magnesium  by  Using  Super  disintegrants,  Res.  J.  Pharm 
and Tech 2008; 1(4): 386-389. 
10.  Kuchekar  BS,  Badhan  AC.  Mouth  dissolving  tablets  of  salbutamol 
sulphate ; a novel drug delivery system, Ind. Drugs 2004; 41(10): 592-
597.  
11.  Shanmungam S, Cendilkumar A. Rapidly disintegrating oral tablets of 
valdecoxib, Ind. Drugs 2005; 42(10): 685-688.  
12. Mishra DN. Rapidly disintegrating oral tablets of meloxicam by direct 
compression method, Ind. Drugs 2006; 43(2): 117-12. 
 
Cite this article as:       
Soumya  Missula,  Yarlagadda  Ankamma  Chowdary,  Gayathri  Pedamallu, 
Kondempudi  Sai  Krishna  Mohan,  Mellacheruvu  Mohana  krishna. 
Formulation and in vitro evaluation of Omeprazole fast dissolving tablets. 
Int.  Res.  J.  Pharm.  2013;  4(8):168-171  http://dx.doi.org/10.7897/2230-
8407.04833  
Source of support: Nil, Conflict of interest: None Declared 